New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
13:15 EDTLPTN, LPTN, REGN, REGN, AGN, AGN, NVS, NVS, RHHBY, RHHBYSummer Street's biotech research team holds analyst/industry conference call
Biotech Analyst Research Team discusses current and future treatments for wet age-related macular degeneration on an Analyst/Industry conference call. Companies which may be discussed include LPTN, REGN, AGN, NVS and RHHBY on an Analyst/Industry conference call to be held on March 19 at 1:30 pm.
News For LPTN;REGN;AGN;NVS;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
08:53 EDTREGNRegeneron price target raised to $560 from $500 at Argus
Argus increased its price target on Regeneron as the firm notes that the company has had positive pipeline and earnings news over the past year, and has increased its sales outlook. Argus thinks the company has a strong pipeline and keeps a Buy rating on the shares.
08:13 EDTLPTNLpath to undergo corporate restructuring
Lpath will restructure its workforce and conduct a strategic evaluation of its research and development programs in order to conserve working capital and focus its resources on those programs deemed most likely to create value in the near term. The company expects that the reduction in workforce together with planned reductions or delays in other expenditures will decrease annualized cash expenditures significantly. With these planned spending reductions, Lpath estimates that its available cash and committed funding should be sufficient to fund the company's drug discovery and development activities through June 30, 2016. Lpath completed a Phase 2a clinical trial of ASONEP in renal cell carcinoma. While that study did not meet its primary endpoint, there were encouraging signals of activity, and Lpath is currently exploring additional indications for ASONEP. Lpathomab is an anti-LPA antibody that is ready to begin a Phase 1 clinical study for neuropathic pain upon clearance from the FDA. Altepan is an anti-leukotriene antibody that is being studied in models of inflammatory bowel disease, respiratory disease and inflammation. Lpath is also applying its proprietary technology to other bioactive lipid targets to create additional novel bioactive-lipid-oriented product candidates for the company's pipeline.
08:11 EDTLPTNLpath's iSONEP for macular degeneration does meet endpoints
Subscribe for More Information
07:38 EDTREGNRegeneron price target raised to $600 from $525 at Canaccord
Canaccord raised its price target on Regeneron to $600 from $525 following positive top-line data for its Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma. The firm sees the data as significant, as it reinforces the role of dupilumab and increases the potential future revenue stream for the company. Canaccord reiterated its Buy rating on Regeneron shares.
May 19, 2015
08:57 EDTNVSLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:55 EDTNVSGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
16:07 EDTRHHBYIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
12:34 EDTREGNRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
12:29 EDTNVSCorium announces publication of data for needle-free transdermal flu vaccine
Corium International announced the publication of "promising" data on the use of its needle-free transdermal system to deliver influenza vaccine in the June 9 issue of Vaccine. The manuscript, entitled "Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs," details results of a preclinical study conducted by Novartis Vaccines (NVS) and Corium. The results demonstrate the compatibility of Corium's MicroCor needle-free transdermal system with cell culture-derived influenza vaccines, and establish its potential as a next-generation vaccine delivery system, the company said.
10:01 EDTRHHBYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A10 Networks (ATEN) upgraded to Overweight from Sector Weight at Pacific Crest... Cal-Maine Foods (CALM) upgraded to Overweight from Equal Weight at Stephens... ChemoCentryx (CCXI) upgraded to Overweight from Neutral at JPMorgan... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Goldman... Chicago Bridge & Iron (CBI) upgraded to Neutral from Sell at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at Goldman... Ctrip.com (CTRP) upgraded to Overweight from Neutral at JPMorgan... Emerge Energy (EMES) upgraded to Buy from Neutral at Goldman... FEMSA (FMX) upgraded to Overweight from Equal Weight at Morgan Stanley... GoPro (GPRO) upgraded to Perform from Underperform at Oppenheimer... Holly Energy (HEP) upgraded to Buy from Neutral at Goldman... JP Energy (JPEP) upgraded on better visibility on volumes at RBC Capital... Laredo Petroleum (LPI) upgraded to Neutral from Sell at Goldman... Malvern Bancorp (MLVF) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Goldman... Norsk Hydro (NHYDY) upgraded to Overweight from Neutral at JPMorgan... Owens-Illinois (OI) upgraded to Neutral from Underperform at BofA/Merrill... Penn National (PENN) upgraded to Buy from Neutral at Goldman... Roche (RHHBY) upgraded to Buy from Neutral at UBS... Schnitzer Steel (SCHN) upgraded on stabilizing headwinds at KeyBanc... Seventy Seven Energy (SSE) upgraded to Buy from Hold at Jefferies... Toll Brothers (TOL) upgraded to Neutral from Underperform at Sterne Agee CRT... United Therapeutics (UTHR) upgraded to Buy from Neutral at BTIG... Volvo (VOLVY) upgraded to Neutral from Underweight at JPMorgan... Zayo Group (ZAYO) upgraded to Buy from Neutral at Goldman.
09:23 EDTRHHBYRoche upgraded to Buy from Neutral at UBS
Subscribe for More Information
07:38 EDTNVSNovartis outlook has improved, says Bernstein
Subscribe for More Information
May 15, 2015
10:29 EDTAGNAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTNVSAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:15 EDTREGNRegeneron target upped to $550 at Credit Suisse citing growth potential
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $450 from $427 at JPMorgan
JPMorgan said it is "increasingly confident" in dupilumab's longer-term prospects in asthma ahead of the full Phase 2b results. The firm believes the drug's peak sales could top $4B. JPMorgan keeps a Neutral rating on Regeneron, however, saying its valuation already reflects blockbuster sales for Eylea, Praluent, sarilumab and dupilumab. It raised its price target for the name to $450 from $427.
May 14, 2015
09:22 EDTRHHBYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
May 13, 2015
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
May 12, 2015
09:26 EDTNVSNovartis Animal Health issued FDA warning letter over marketing materials
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use